Alzheimer’s is the most common form of dementia — it causes memory loss, confusion, thinking problems and behavioral changes.

A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests ...

Posdinemab works by targeting and neutralizing Alzheimer disease-specific phosphorylated tau, preventing its spread to other neurons.

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Posdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific ...

GROUNDBREAKING research has shown that chronic intestinal infections caused by cytomegalovirus (HCMV) may play a role in a ...